Service de Biomédecine, Laboratoire des Catécholamines et Peptides, University Hospital of Lausanne, 1011 Lausanne, Switzerland.
Best Pract Res Clin Endocrinol Metab. 2013 Oct;27(5):713-23. doi: 10.1016/j.beem.2013.06.004. Epub 2013 Jul 9.
For more than 20 years, measurement of catecholamines in plasma and urine in clinical chemistry laboratories has been the cornerstone of the diagnosis of neuroendocrine tumors deriving from the neural crest such as pheochromocytoma (PHEO) and neuroblastoma (NB), and is still used to assess sympathetic stress function in man and animals. Although assay of catecholamines in urine are still considered the biochemical standard for the diagnosis of NB, they have been progressively abandoned for excluding/confirming PHEOs to the advantage of metanephrines (MNs). Nevertheless, catecholamine determinations are still of interest to improve the biochemical diagnosis of PHEO in difficult cases that usually require a clonidine-suppression test, or to establish whether a patient with PHEO secretes high concentrations of catecholamines in addition to metanephrines. The aim of this chapter is to provide an update about the catecholamine assays in plasma and urine and to show the most common pre-analytical and analytical pitfalls associated with their determination.
20 多年来,临床化学实验室中血浆和尿液儿茶酚胺的测量一直是神经嵴来源的神经内分泌肿瘤(如嗜铬细胞瘤[PHEO]和神经母细胞瘤[NB])诊断的基石,并且仍然用于评估人和动物的交感神经应激功能。尽管尿液儿茶酚胺的测定仍被认为是 NB 诊断的生化标准,但为了支持/确认 PHEO,它们已逐渐被甲氧基肾上腺素(MNs)取代。然而,儿茶酚胺的测定对于改善 PHEO 在通常需要可乐定抑制试验的困难情况下的生化诊断仍然很有意义,或者确定 PHEO 患者是否除了甲氧基肾上腺素外还分泌高浓度儿茶酚胺。本章的目的是提供关于血浆和尿液儿茶酚胺测定的最新信息,并展示与其测定相关的最常见的分析前和分析错误。